Physician profile
Kurt Ramey
NPI 1942886726
$1,072.08
in general payments reported to CMS, 2019-2025
11 companies · $449 in 2025
The $449 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.92 · 2023: $217 · 2024: $389 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,040 · Travel and Lodging: $15.23.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.93 |
| Travel and Lodging | $15.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $239.10 | 2024 | Micra, Cobalt Dr Mri Surescan |
| Astrazeneca Pharmaceuticals LP | $199.01 | 2023 | Farxiga |
| Cvrx, INC. | $150.77 | 2025 | Barostim Neo System |
| Penumbra, INC. | $131.62 | 2025 | Indigo System |
| Inari Medical, INC. | $108.91 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Stryker Corporation | $76.31 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Abiomed | $72.92 | 2025 | |
| Novartis Pharmaceuticals Corporation | $40.61 | 2024 | |
| Glaxosmithkline, LLC. | $18.14 | 2023 | Trelegy Ellipta |
| Pfizer INC. | $17.77 | 2025 | |
| Vanda Pharmaceuticals INC. | $16.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Ramey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.